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Abstract
Background: The ever increasing burden of breast cancer, the most common cancer among 
women, demands a diagnostic test that is rapid, reliable, informative and cost-effective; 
particularly in countries with limited financial and medical resources. FNAB cytology and 
cell block combination has gained worldwide utility and has been described to be accurate 
and reliable.  
Aim: Henceforth the aim of this study was to retrospectively correlate the expression of 
prognostication markers, namely, estrogen receptor (ER), progesterone receptor (PR) and 
human epidermal growth factor receptor 2 (HER2) performed on cell blocks (using the BD 
CytorichTM Red method) and formalin-fixed, paraffin-embedded cell blocks (FFPET) in 
chemotherapy naive breast carcinomas, by immunochemistry (immunocytochemistry and 
immunohistochemistry respectively) and to perform fluorescence in-situ hybridization (FISH) 
testing for over- expression of the HER2 gene.  
Methods: Between 2013 and 2016, 132 cases of primary breast carcinoma were identified 
that had both cytology (including Cytorich™ Red cell blocks) and histology specimens that 
were both chemotherapy naive. Immunostaining for ER, PR and HER2 was performed.  The 
staining was scored according to the Allred scoring system for histology specimen and this 
system was slightly adapted for cytology specimens, which also took the American Society of 
Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines into account. 
FISH for HER2 over-expression was performed. The grade of the carcinoma was also 
analysed on both the cytology specimens (using the Robertson’s grading system) and the 
histology specimens (using the Modified Elston & Ellis system).  
Results: ER and PR performed on cell blocks had good correlation with FFPET with 91% 
and 85% sensitivity, respectively. HER2 on cell blocks had an agreement of 88% with 
FFPET. 87.88% of cell blocks had more than a 100 tumour cells present on H&E sections 
and cytological grading had an agreement of 41.41% with histological grading. 
Conclusion: The cell block technique continues to play a vital role in the diagnosis of 
primary, recurrent and metastatic breast carcinoma, allowing assessment of prognosis and 
prediction of response to therapy. 
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Abstrak 
Agtergrond: Borskanker is die allergrootste las wat op vouens rus en is die mees 
algemeenste kanker onder vroue. As gevolg hiervan is diagnostiese toetse wat vinnig, 
bertroubaar en insiggewend is belangrik, veral in lande met beperkte mediese en finansiële 
hulpbronne. Fyn naald aspirasie en die selblok kombinasie het wêreldwyd nut verwerf en 
word beskryf as ‘n betroubare en akkurate toets.  
Doelwitte: Die doelwit van hierdie studie was om retrospektief te korreleer of voorspelling 
merkers, naamlik estrogeen reseptor (ER), progesteroon reseptor (PR) en menslike 
epidermale groei faktor reseptor 2 (HER2) uitgevoer op selblokke (met gebruik van die BD 
Cytorich ™ Red metode) en formalien gefikseerde, paraffien inbedding weefsel blokke in 
chemoterapie naἲve borskarsinome te korreleer deur immunochemie. Die uitvoering van 
FISH toetse vir die oor uitdrukking van die HER2 geen was ook gedoen. 
Metodes: Tussen 2013 en 2016 was 132 gevalle geidentifiseer met ‘n primêre diagnose van 
borskarsinoom, wat albei sitologie (insluitend BD Cytorich™ Red selblokke) en histologie 
monsters het. Immunokleuring vir ER, PR en HER2 was gedoen en die kleuring was deur ‘n 
puntestelsel volgens die Allred stelsel vir histologie gedoen wat egter effens aangepas vir 
sitologie selblokke was. Die Amerikaanse vereniging van kliniese onkologie (ASCO)/ 
kollege van amerikaanse patoloë (CAP) riglyne was ook toegepas vir HER2 ontleding asook 
FISH toetse vir HER2 ekspressie. Die gradering van karsinome was ook geontleed vir beide 
sitologie monsters met aanwending van die Robinson’s gradering sisteem en vir histolgie 
monsters met aanwending van die gemodifiseerde Elston en Ellis sisteem.  
Resultate: ER en PR uitgevoer op selblokke het goeie korrelasie met weefsel blokke getoon 
met ‘n sensitiwiteit van 91% en ‘n spesifisiteit van 62% vir ER en ‘n sensitiwiteit van 85% en 
spesifisiteit van 84% vir PR. HER2 op selblokke het ‘n ooreenstemming van 88% gehad met 
weefsel blokke en 87.88% van die selblokke het meer as 100 tumor selle teenwoordig gehad 
op H&E snitte. Gradering van sitologie het ‘n ooreenstemming van 41.41% met histologie 
gradering gehad. 
Gevolgtrekkinge: Die selblok tegniek speel ‘n belangrike rol in die diagnose van primêre, 
terugkerende en metastase van borskarsinoom. Terselfte tyd word die berekening van 
prognose toegelaat asook die voorspelling van toepaslike behandeling. 
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Chapter 1: Literature review 
1.1 Breast cancer background 
1.1.1 Incidence and mortality 
In both developed and developing countries, breast cancer has now become the most common 
malignancy in women. In South Africa breast cancer accounts for 19.4% of all cancers 
observed in women compared to 10% worldwide as recorded in 2008.1 In 1997 about 
895 000 of new breast cancer cases were reported with 467 000 deaths worldwide.2 However, 
in 2008 about 1 384 155 new cases were calculated from population-based cancer registries 
and 459 000 deaths were recorded.2,3 
Globocan 2012 statistics indicated a startling 1.7 million women that were diagnosed with 
breast cancer and 522 000 related deaths.3 The current life expectancy in South Africa is 45 
years whereas life expectancy in developed countries is 82 years of age.1 Aetiology and 
pathological characteristics of breast cancer are highly heterogeneous. Thus some tumours 
demonstrate a slow growth pattern with excellent prognosis whereas others demonstrate a 
highly aggressive clinical progression and poor outcome. Women in developing countries 
tend to have a poorer prognosis and the incidence rate is expected to increase further, mainly 
due to adoption of a more westernised lifestyle(s), with little or no physical activity and 
delayed child bearing.3,4 However, early diagnosis and onset of treatment, improved 
treatment modalities and screening programs have created discrepancies between incidence 
and mortality.2 
Mammography and improved therapies have allowed breast cancer to be detected earlier in 
developed countries.5 South Africa has relatively sparse information regarding cancer 
incidence and mortality data; and having population based cancer registries can become very 
important in breast cancer surveillance.6 
1.1.2 Risk Factors 
Large differences exist between the geographical zones that demonstrate a high risk for breast 
cancer. The large differences may be due to variations in genetics, lifestyle and 
environmental factors.2 
Age is however considered a major risk factor of breast cancer and cancer in general. A vast 
majority of breast cancer occur in women older than 50 years of age.2 More worrying is the 
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2increase of breast cancer in women under 45 years of age. Age is however not the sole 
contributing factor. In addition to age,  other risk factors include diet, reproductive and 
hormonal changes, genetics, exposure to chemical and hazardous substances, radiation, 
tobacco smoking, alcohol consumption as well as numerous unknown factors.2 
The role of BRCA1 and BRCA2 gene expression in the aetiology of breast cancer has been 
studied extensively. These genes are classified as tumour suppressor genes and are mainly 
involved in DNA repair, transcriptional regulation, genomic stability and cell cycle control. 
However a disruption of these genes may increase risk for breast cancer development.  The 
estimated life-time risk for breast carcinoma in women expressing these genes is between 50-
80% compared to a risk of fewer than 10% for the general population. Therefore having 
knowledge of their presence in any individual allows for regular follow up for early 
diagnosis, quicker initiation of treatment and improved overall survival.2,7 
Recent studies regarding hormones and its effects on breast cancer risk confirm that woman 
who had early menarche, remain nulliparous, have delayed childbearing, lack of 
breastfeeding, late onset of menopause or exposure to endogenous and exogenous estrogen 
hormones most frequently develop breast cancer.2,8 
Estrogen is essential in cancer initiation and development and prolonged exposure to estrogen 
and progesterone contribute to the development of breast cancer. Removal of endogenous 
estrogen by oophorectomy decreases risk, but the primary source of estrogen in 
postmenopausal women is adrenal gland derived androgenic precursors, converted with the 
aid of aromatase enzymes to estrogen in adipose tissue. Therefore increased body fat leads to 
increased estrogen levels in postmenopausal women and they are more likely to develop 
breast cancer.2,8 
1.1.3 Structure of the breast 
The breast consists of 15 to 25 independent glandular units named breast lobes, each 
consisting of several lobules and compound tubule- acinar glands. These lobes are embedded 
in a network of adipose tissue that is subdivided by collagenous septa. The lobes are arranged 
radially at different depths around the nipple. The lactiferous duct is a single large duct, 
draining each lobe via a separate opening on the surface of the nipple. The lactiferous sinus is 
a dilation formed by the duct before opening onto the surface.  
Each breast lobe is divided into variable numbers of breast lobules and each lobule consists 
of a system of ducts. Lobules are separated by moderately dense collagenous interlobular 
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tissue, whereas the intra- lobular supporting tissue surrounding the ducts within each lobule is 
less collagenous and more cellular.9  
 
Figure 1.1 Anatomy of the female breast (https://www.kullabs.com/uploads/image00154.jpg) 
 
1.1.4 Breast Pathology 
Breast cancer is an epidemic that extensively affects women of all ages and race.2 Breast 
pathology plays a vital role in the assessment of breast disease by providing initial diagnosis, 
prognosis and prediction of treatment (theranostics).  
Material from the breast can be collected for pathological examination via either: fine needle 
aspiration biopsy (FNAB) for cytological diagnosis, or core needle biopsy or surgical 
excision for histological diagnosis. These techniques can be used to make a diagnosis of 
breast carcinoma, and to determine a particular tumour’s susceptibility to hormonal therapy 
or the recently introduced Trastuzumab® for HER2 over-expression. The pathology report 
must be informative and accurate and should include factors important for prognosis and 
treatment, such as tumour size, type, grade, lymph node involvement and presence of 
vascular invasion.10 
1.1.5 Types of Breast Carcinomas 
1.1.5.1 Carcinoma in- situ 
Carcinoma is the most common malignant neoplasm of the breast. Distinction between 
carcinoma in-situ and invasive carcinoma is important due to different treatment protocols. 
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At time of diagnosis carcinoma in-situ may be clinically asymptomatic, presents with 
mammary Paget’s or with similar signs and symptoms as invasive carcinoma.  
Ductal carcinoma in-situ (DCIS) is the proliferation of neoplastic epithelial/ductal cells 
within the breast ducts, which are limited by the basement membrane. DCIS may occur alone 
or in conjunction with invasive carcinoma. Immunohistochemistry increases the accuracy of 
histological diagnosis by visualization of the outer layer of myoepithelial cells. The 
myoepithelial cell layer is present in most benign lesions (except for micro-glandular 
adenosis) but is absent in invasive carcinoma. DCIS is curable by surgical excision, but 
mastectomy may be required in cases of extensive or multifocal disease.10 
   
Figure 1.2 (a) Histological section indicating DCIS with malignant ductal epithelium limited to the 
basement membrane. (H&E stain x100). (b) Histological section indicating DCIS with the 
myoepithelial cell layer (arrow) that lines the basement membrane. (H&E stain x400) 
 
Lobular neoplasia is a neoplastic change occurring within breast lobules and can range from 
atypical hyperplasia to lobular carcinoma in-situ (LCIS). LCIS is usually diagnosed 
incidentally on biopsy. LCIS is a risk factor for the subsequent development of invasive 
lobular cancer. Regular observation of patients is the preferred management option rather 
than surgery, although more aggressive subtypes such as pleomorphic LCIS may require 
surgical excision.11  
1.1.5.2 Invasive carcinoma, NST (invasive ductal carcinoma, NST) 
Invasive carcinoma, NST (IDC, previously known as invasive ductal carcinoma most often 
presents as a palpable breast mass and in some instances with skin retraction or nipple 
discharge. Nipple abnormalities include ulceration, retraction, and eczematous reaction as the 
cancerous cells grow into the epidermis of the nipple, called Paget’s disease of the breast. 
Small asymptomatic tumours may only be identified by mammography. Invasive tumours can 
A B 
A B 
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vary in size and can have an irregular, stellate outline or nodular configuration. Tumour edge 
is usually moderately to ill-defined and lacks sharp circumscription. These tumours are hard 
and firm on palpation with a gritty consistency when cut with a knife. Carcinoma of no 
special type (NST) is the most common and comprises about 75% of all breast carcinomas. It 
occur more frequently in women older than 40 years. Invasive carcinoma has variable clinical 
presentations and pathological features. The numerous types of breast carcinoma, as defined 
by the current WHO classification, show a wide spectrum of morphological features and 
grades, which create significant challenges to the cytological diagnosis of breast cancer.12 
Cytological aspirates are usually very cellular, composed of single cells and loosely cohesive 
cell groups. The single cells may have eccentric nuclei with intra-cytoplasmic lumina that 
may contain mucin droplets. Nuclear atypia varies depending on the grade of the tumour; 
from monomorphic small nuclei with vesicular chromatin to extremely pleomorphic, large 
nuclei with clumped, irregular chromatin chards. The background of smears varies from clean 
to necrotic or haemorrhagic. A limiting factor is that in-situ  carcinoma cannot always be 
reliably distinguished from invasive carcinoma on cytology; however the absence of 
myoepithelial cells and abundant discohesion of tumour cells are helpful features in 
establishing a diagnosis of invasive carcinoma.12 
   
 
Figure 1.3 (a) Ductal carcinoma with cellular discohesion and nuclear pleomorphism. (Papanicolaou 
stain x400). (b) Ductal carcinoma with single cells, eccentric nuclei and large pleomorphic nuclei. 
(Papanicolaou stain x400). 
 
IDC is histologically graded in Grades I, II and III by interpreting architectural arrangements 
(amount of tubule formation), mitotic count and nuclear pleomorphism; according the 
Modified Bloom and Richardson System. The presence or absence of DCIS is reported as is 
A B 
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the grading and extent of the DICS.  Key features include prominent gland formation and 
infiltration of benign fibroadipose tissue.12 
   
 
Figure 1.4 (a) Histological section showing invasive carcinoma, NST. (H&E stain x100). (b) 
Histological section showing invasive carcinoma, NST with pleomorphic nuclei. (H&E stain x200). 
 
1.1.5.3 Invasive Lobular carcinoma 
Lobular carcinoma comprises about 5–10% of all breast carcinomas and is the second most 
common breast carcinoma with a prognosis being better than the more common invasive 
carcinoma, NST.13 Approximately 70-95% of lobular carcinomas are ER-positive and 60-
70% are PR positive whereas HER2 expression is rare. Marked fibrosis may account for low 
or inadequate cellular yield on FNA. The subtle morphology of cells, low proliferative 
activity, and diffuse multi-focal growth pattern make it difficult to diagnose lobular 
carcinoma on cytology.12,13 
Cytological aspirates usually have sparse cellularity with mostly single intact cells and few 
loosely cohesive groups. Cells are small to medium sized with a plasmacytoid appearance. 
Cytoplasm is scant to moderate and intra-cytoplasmic vacuoles may be prominent. Nuclei are 
small and eccentric with slight atypia and irregular membranes with small to inconspicuous 
nucleoli. Histological diagnosis includes observing small cells with eccentric round oval 
nuclei and intra-cytoplasmic lumina. Cells are usually arranged in discohesive groups, cords 
or singly dispersed, typically growing in a concentric fashion around native breast ducts.12   
A B 
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Figure 1.5 (a) Lobular carcinoma showing scant to moderate cytoplasm, eccentric nuclei and irregular 
nuclear membranes. (Papanicolaou stain x1000). (b) Lobular carcinoma illustrating small to medium 
sized cells with plasmacytoid appearance. (MGG stain x400) 
 
   
 
Figure 1.6 (a) Histological section illustrating invasive lobular carcinoma consisting of rather 
discohesive, loose lying, single intact cells. (H&E stain x200). (b) Histological section showing 
invasive lobular carcinoma with discohesive, plasmacytoid appearing cells with eccentric, low grade 
nuclei. (H&E stain x400) 
 
1.1.5.4 Mucinous carcinoma 
Mucinous (colloid) carcinoma accounts for approximately 2% of all breast carcinomas and is 
a mucin producing tumour with a favourable prognosis. This tumour usually occurs over a 
wide age range and may present with a palpable mass. They are usually well-circumscribed, 
soft and gelatinous. ER positivity is common and PR positivity is observed in less than 70% 
of mucinous carcinomas while HER2 over-expression is uncommon.12 
 
A B 
A B 
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Cytological characteristic of mucinous carcinoma is the presence of abundant mucinous 
matrix found in the background. Mucin appears metachromatic on MGG stain and green-
purple on Papanicolaou stain. The malignant cells are bland with uniform nuclei and cells 
usually form ball like aggregates floating in the mucin pools.12 
   
 
Figure 1.7 (a) Mucinous carcinoma illustrating abundant mucinous matrix in the background. 
(Papanicolaou stain x400). (b) Mucinous carcinoma with ball-like cellular tissue fragments floating in 
a sea of mucin. (Papanicolaou stain x400) 
 
Histological features are similar to cytology with the presence of abundant extracellular 
mucin. The cells form tight three dimensional balls floating in mucin. Papillary, gland and 
trabecular arrangements can be observed. Minimal to mild nuclear atypia are seen with 
mitotic figures not usually observed. 
   
 
Figure 1.8 (a) Mucinous carcinoma illustrating abundant extracellular mucin in the background (H&E 
stain x100). (b) Mucinous carcinoma showing bland uniform nuclei. (H&E stain x400). 
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1.1.5.5 Carcinoma with medullary features (Medullary carcinoma) 
Medullary carcinoma accounts for approximately 1-7% of all breast carcinomas and carries a 
better survival rate. These tumours are usually triple negative; ER, PR and HER2 negative.12 
Cytological aspirates are highly cellular and show marked atypia (high grade nuclear atypia) 
with bizarre nuclei which contain stripped chromatin and large nucleoli. The cytoplasm tends 
to be more abundant with indistinct cytoplasmic borders. Lymphoplasmacytic response in the 
background may raise the possibility of a medullary carcinoma but histological diagnosis is 
mandatory.12 As the criteria for diagnosing medullary carcinoma are histology based, 
cytology may suggest this diagnosis, but final subtyping is deferred to the excision specimen. 
Histological features include a well circumscribed mass, syncytial growth pattern in more 
than 75% of the tumour and absence of tubule formation. The presence of marked 
lymphoplasmacytic infiltration and marked nuclear pleomorphism aids in the diagnosis.12 
   
 
Figure 1.9 (a) Medullary carcinoma showing marked nuclear atypia. (Papanicolaou stain x200). (b) 
Medullary carcinoma showing pleomorphic bizarre shaped nuclei and lymphocytic infiltrate on the 
right. (H&E stain x400) 
 
   
 
Figure 1.10 (a) Medullary carcinoma indicating a lymphoplasmacytic infiltrate top right corner. (H&E 
stain x200). (b) Medullary carcinoma showing lymphoplasmacytic infiltrate and marked nuclear 
pleomorphism. (H&E stain x400) 
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1.1.5.6 Papillary carcinoma 
Invasive papillary carcinoma accounts for 1-2% of all breast carcinomas and has a favourable 
prognosis. Common clinical presentations include palpable peri-areolar mass, skin dimpling, 
bloody nipple discharge and nipple retraction. ER and PR positivity are usually observed and 
HER2 over- expression is rarely seen. Cytological diagnosis is based on very cellular 
aspirates showing papillary clusters with uniform tall and columnar cells surrounding true 
fibro vascular cores. Myoepithelial cells are usually absent. Nuclei may show varying degrees 
of atypia and appear elongated and bland. Occasional necrotic debris, blood in background 
and haemosiderin-laden macrophages may be seen.12 Histological features include the 
presence of cellular islands surrounding fibro vascular cores. The evaluation of core biopsy is 
challenging due to the broad spectrum of papillary lesions. Apocrine differentiation and 
amphiphilic cytoplasm with moderately atypical nuclei may be present.12 
    
 
Figure 1.11 (a) Papillary carcinoma showing papillary clusters surrounding fibro vascular cores. 
(Papanicolaou stain x400). (b) Cell block section indicating papillary clusters. (H&E stain x100). 
 
   
 
Figure 1.12 (a) Papillary carcinoma. (Papanicolaou stain x400). (b) Papillary carcinoma showing true 
fibrovascular cores. (Papanicolaou stain x100) 
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1.2 Histopathology 
Histopathology is more informative and is considered the golden standard in the diagnosis of 
breast carcinoma. Core needle biopsy or surgical excisional biopsy for palpable breast lesions 
can be performed to obtain tissue for histological diagnosis. Stereotactic core needle biopsies 
can be performed on non-palpable lesions enabling accurate sampling of a small lesion and 
distinguishing between in-situ and invasive carcinoma.14,15 Advantages of core needle 
biopsies include providing a diagnosis of breast abnormality as well as avoiding open 
surgery.16 
Core needle biopsies, however, have numerous disadvantages such as being time-consuming, 
requiring anaesthesia and a highly trained operator (specialist surgeon or experienced medical 
doctor) to avoid pitfalls and complications and to yield representative results. Pitfalls and 
complications may arise if the correct sized needle is not used, with non-sampling of micro-
calcifications, and if an inexperienced operator performs the procedure. Core needle biopsy is 
the better option when FNAB is not available or has failed to produce a diagnosis.17  
However, core needle biopsy in the majority of cases allows for a definitive diagnosis that 
enables patients to receive prompt treatment. Clinical complications after core needle biopsy 
are low, with pneumothorax being a possible major complication.16 Histological features of 
carcinomas seen in core needle biopsy correlate with the features seen in excised tumours.15 
Additionally, it allows for the determination of histological prognostic factors such as the 
type of tumour, grade, invasion, and the immunohistochemical assessment of ER, PR, and 
HER2 status. It remains unclear if the cores obtained are representative of a whole tumour 
because the distribution of antigens could be heterogeneous.18 
Surgical excision of a breast lesion is considered the gold standard in the assessment of 
prognostic factors and is the method of choice when minimally invasive methods such as 
FNAB and core needle biopsy have failed. Excisional biopsy is expensive and has a greater 
degree of patient morbidity.18,19 Core needle biopsy, on the other hand, is less invasive and in 
most instances can provide an accurate preoperative diagnosis.20 
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1.3 The Triple Assessment 
The triple assessment comprises a combination of the clinical examination of the patient, and 
the radiological evaluation (mammography/ultrasound) and either core needle biopsy or 
FNAB of the breast lesion. This approach enables accurate, pre-operative diagnosis in breast 
pathology, and it is the most widely used test for lesions identified through screening 
programs or for patients presenting with symptoms.10,21 
Clinical assessment involves a thorough history and physical examination of both breasts and 
regional lymph nodes. The most common clinical signs of breast cancer include a discrete 
lump or asymmetric thickening. Nipple retraction, skin dimpling, inflammation, swelling, 
oedema, bloody or serous nipple discharge, and nipple eczema are other signs indicative of 
breast carcinoma.11 
Radiological assessment includes mammography and ultrasound which are the primary 
imaging modalities currently used. Mammography is less sensitive in younger patients (under 
30 years of age), but it is the baseline method used in women over 40 years of age.22 
Ultrasound is suitable for women of all ages, and it is a useful tool for the evaluation of focal 
abnormalities, to determine if a lesion is solid or cystic, and in distinguishing benign from 
malignant (cystic) lesions.11 Breast ultrasound  has a sensitivity of approximately 93% and 
specificity of 97% in detecting breast carcinoma.23 Mammography can support the diagnosis 
of suspicious for malignancy, record the extent of a malignant tumour and identify other non- 
palpable lesions.24 
The diagnostic accuracy of breast FNAB is comparable to core biopsy when combined with 
physical examination and mammography, with a diagnostic error rate of less than 1% if used 
in the context of the triple test. If the triple test components are not in agreement or if FNAB 
results are equivocal or insufficient, a repeat FNAB or core needle biopsy or a larger tissue 
biopsy (such as surgical excision) should be performed.10,21 
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1.4 Fine Needle Aspiration Biopsy (FNAB) 
Reducing discomfort for patients and using the least invasive technique to obtain a diagnosis 
is the ultimate goal of cytology. Cytology allows for quick, reliable diagnosis and facilitates 
programs for cancer diagnosis within a population.25 FNAB is a widely accepted technique 
that can provide good quality material for routine diagnostic smears as well as cell block 
preparations that can be used for ancillary prognostic tests. 26 
Numerous studies confirmed that FNAB is a simple, rapid, cost-effective, and outpatient 
procedure.27–30 FNAB is performed on clinically palpable lesions in clinical settings where a 
core biopsy is not available. The required level of expertise to perform FNAB is much less 
than for core needle biopsy and can be performed by trained nursing personnel and medical 
doctors who have not been trained in core needle biopsy techniques. 
FNAB is also helpful to characterize breast tumours and to evaluate patients with primary, 
recurrent and metastatic disease.31 Breastfeeding or lactating patients who are at higher risk 
of developing galactocele or milk fistula after core biopsy benefit from FNAB.  
For FNAB to be successful and accurate, FNAB aspirators need to be adequately skilled, to 
produce aspirates of adequate quality for diagnosis, and to have access to ancillary 
investigation material (i.e. cell blocks). Experienced cytologists/cytopathologists should 
interpret FNAB derivatives, including smears and cell blocks .32 
FNAB has few complications, mostly in the form of minor bruising or bleeding at the site of 
puncture.33 Needle tract seeding is not a risk with FNAB breast specimens, which also holds 
for a core needle biopsy that creates an even larger tract.  
The major pitfalls or disadvantages of FNAB specimens include: 
• The need for high quality, cellular, and well-preserved material;  
• Interpretation by experienced cytopathologists/cytotechnologists;  
• Challenges to distinguish between invasive and in-situ carcinoma;  
• The patient needs access to the triple test;  
• Limitations to classify papillary lesions into benign or malignant with adequate 
sensitivity for diagnostic applications and clinical management of the patient.  
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Figure 1.13 Illustration of processing of a cytology breast FNAB specimen. 
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1.5 Cell Block Evolution 
The use of cell blocks began a century ago and had become a routine service in many 
cytopathology laboratories. Bahrenburg first reported this technique in 1896 when he 
described an innovative method that was applied to ascitic fluid. Nowadays, various 
techniques are available, using different types of fixative and processing. The most common 
variants include the collodion bag technique, the thrombin method, the Millipore filtration 
method, the saline needle rinse method, the histogel method, and filter sedimentation and 
agar embedding.30,34  Although all the different cell block methods differ with regards to the 
types of fixatives, materials, and techniques used, the underlying principle remains the same. 
The common denominator comprises of the concentration of cells by centrifugation, followed 
by removal of the supernatant and adding a binding agent to form a cohesive pellet, followed 
by processing according to standard histological procedures. 
However cell block preparation methods and collection media are not yet standardized. Many 
of these methods are time-consuming and labour intensive, especially in the current era of 
strict turnaround times that apply in routine cytopathology laboratories. The different 
techniques also require variable technical skills that may lead to inconsistent results.35 A wide 
variety of fixatives are also available for cell block preparations. Some fixatives such as B5 
solution, which contains mercury, is not acceptable due to health hazards. Other fixatives 
such as ethanol provide optimally preserved nucleic acid and for eliminating background 
staining such as obscuring blood. Thus nucleic acid quality in alcohol-based fixatives may be 
superior compared to formalin-fixed tissue blocks.34  
Cell blocks on the other hand can be easily stored to provide material for future research 
purposes; multiple sections can be cut from adequately cellular cell blocks for ancillary tests. 
The cell block technique has gained wide utility as a platform to perform ancillary tests and 
has been validated by many studies to be accurate, reliable and comparable to tissue 
blocks.27,29,36 Ancillary tests include immunocytochemistry, special stains, molecular 
analyses, cytogenetics, polymerase chain reaction (PCR) and in-situ hybridisation.28–30 Cell 
blocks often offer well-preserved cellular detail and morphological architecture, which can 
closely resemble histopathological features seen on tissue biopsies, thereby facilitating in 
diagnosis and pattern recognition.30,37 
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Sampling type, specimen size and aspiration techniques all contribute to the diagnostic 
accuracy and sensitivity of cell blocks, which can vary between 60% and 90%. Combining 
cell blocks with conventional smears improves diagnostic accuracy to 90%.30,37  
1.6 Estrogen and Progesterone hormone Receptors 
Estrogen Receptor (ER) is the most informative biomarker for breast carcinoma and the most 
important prognostic and predictive indicator.5 ER is a nuclear hormone receptor that acts as 
a ligand-activated transcription factor. Carcinomas that are ER-positive tend to be well- 
differentiated, less aggressive and have an overall better prognosis (as compared to ER-
negative cancers). ER-positive carcinomas account for approximately 75-80% of breast 
carcinomas and respond well to endocrine therapy. Greater benefit from endocrine therapy is 
observed in tumours that express higher levels of ER. Lobular carcinoma, mucinous (colloid) 
carcinoma, pure tubular carcinoma and virtually all grade 1 invasive carcinomas, NST 
express ER positivity.5,38,39 
Progesterone receptor (PR) is an estrogen-regulated gene, expressed by 50% of ER-positive 
tumours; thus the expression of PR is highly dependent on the presence of ER. Tumours that 
are ER-positive and express low or absent PR expression are more proliferative, aggressive, 
have a poorer prognosis and develop recurrence.5 However, tumours expressing both ER and 
PR have a more favourable prognosis and respond better to endocrine therapy. It is 
uncommon to have ER absent and detectable PR expression, which may be largely due to 
false negative ER or false positive PR, but not all cases account for technical errors. ER-
negative and PR positive tumours are infrequently recorded, but despite limited evidence that 
indicates benefit from endocrine therapy, these cases are typically treated with endocrine 
therapy.5,39  
PR and ER expression are associated with disease-free and improved overall survival. Thus 
accurate and quantitative assessment of results is critical in determining therapy.  Several 
major factors can affect ER and PR status including tissue fixation and choice of anti-ER or 
anti-PR antibodies.38 ER and PR status can be determined via IHC, which is easy, safe, 
specific and cheap for evaluating cytological material, fresh frozen tissue or formalin-fixed 
paraffin- embedded tissue specimens.40 
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1.7 Human Epidermal growth factor Receptor (HER2) 
HER2 (or c-erb B2) proteins are members of subclass 1 of the receptor tyrosine kinase 
superfamily. The subgroup tyrosine kinase consists of four members including epidermal 
growth factor receptor (EGFR/ erbB1/ HER1), erbB2/ neu/ HER2, erbB3/ HER3 and erbB4/ 
HER4.  HER1 and HER2 play a strong role in neoplastic transformation in vitro and in vivo. 
Normal breast epithelium express low levels of HER2 but overexpression of HER2 occurs in 
about 20- 30% of all breast carcinomas usually due to gene amplification, and 50% of these 
cases are shown to be ER-negative.7,22,38 
HER2 is located on chromosome 17q21 and promotes tumour growth by regulating cell 
growth, differentiation, survival, migration and cellular responses through numerous 
signalling pathways.41 The expression of HER2 usually indicates poor prognosis and 
aggressive behaviour but is a strong predictive biomarker to predict sensitivity to 
anthracycline-based chemotherapy regimens.  
Trastuzumab is a monoclonal antibody attached to a chemotherapy drug that binds to the 
extracellular domain of HER2. Treatment with Trastuzumab® has been shown to markedly 
improve response rate and survival of breast carcinomas overexpressing HER2 oncogene.38,39 
The American Society of Cancer Oncology (ASCO)/ College of American Pathologists 
(CAP) guidelines allow for routine evaluation of HER2 status on all primary and metastatic 
breast carcinomas to determine whether tumours are positive, equivocal or negative. 
Equivocal HER2 expression needs further assessment with fluorescence in- situ hybridization 
(FISH) to furthermore determine HER2 status as positive or negative.5,39 
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1.8 Fluorescent in situ hybridization 
HER2 in-situ hybridization assays are aimed to visualize the HER2 gene with or without the 
reference target chromosome 17 centromere (CEN17) in tissue samples. The American Food 
and Drug Administration (FDA) has approved multiple signal detection systems for HER2 
assays; namely fluorescent in-situ hybridization (FISH); chromogenic in-situ hybridization 
(CISH) and dual in-situ hybridization (DISH). HER2 FISH assays are performed by using 
manual or semi-automated protocols and a specialized fluorescent microscope to perform 
subsequent analysis in a dark room. HER2 ISH assay  assessment comprises quantitative 
analysis, which includes assessment of internal control cells that are adjacent to tumour cells 
in the same tissue section.42 
1.9 Breast cancer management 
Surgery is the primary treatment for in-situ carcinoma and it aims to excise the entire in-situ 
tumour and minimise local recurrence.  Local recurrences after breast-conserving therapy for 
DCIS display invasive carcinoma in 50% of the cases.  The most effective treatment for 
DCIS is tumour excision or mastectomy, with or without either anti-hormonal treatment or 
postoperative radiotherapy.  Tumour size and focality, grade, necrosis (punctate or comedo), 
as well as margin status and age of patient are critical elements in the reporting of DCIS.22 
Surgery is the first line of treatment for operable primary invasive breast carcinomas, with or 
without involved axillary lymph nodes. Surgical options include mastectomy or breast-
conserving procedures. The latter consists of the removal of a tumour with clear excision 
margins followed by postoperative radiotherapy. 
Adjuvant treatment is given after surgical removal of a tumour and includes local treatment 
such as radiotherapy and systemic treatments. Adjuvant treatment aims to increase overall 
survival, improve disease-free and reduce the risk of local recurrence.43 
Neoadjuvant treatment is chemotherapy given as the first line of treatment and administered 
before surgery for locally advanced breast cancers. The ultimate aim of neoadjuvant 
treatment is to reduce the size of a tumour to permit breast-conserving surgery. Assessment 
of the carcinoma’s response to treatment involves the careful assessment and monitoring of 
tumour size.10,11,43 
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1.10 Breast cancer grading 
Tumour grading before surgery is important to select the most suitable treatment regimen. 
Elston & Ellis’s modification of the Scarff-Bloom-Richardson (SBR) grading system is a 
widely accepted tumour grading system performed on histological tissue and has been found 
to have a good prognostic correlation.  
Cytological grading is not routinely utilised as compared to histological grading but can be a 
useful parameter for early breast cancer, especially when selecting neoadjuvant therapy. 
Various grading systems have evolved for FNA cytology based on cytological features. 
Grading of FNA material should be incorporated for prognostication in the era of 
neoadjuvant therapy. Patients with locally advanced disease, who declines surgery and older 
patients with accompanying chronic diseases may benefit from grading of tumours on FNA.  
The Robinsons grading system is based on simplicity, specificity and reproducibility and 
useful for the grading of breast carcinoma on FNA material. Previous studies showed 
concordance rates ranging from 56.9% to 89.1% on FNA when compared to histological 
grading.44 
Hence obtaining a rapid diagnosis of a breast carcinoma expedites the referral of patients to 
appropriate treatment centres and timely initiation of treatment, whereas a delay in the 
diagnosis of breast cancer reduces overall survival and increases morbidity. The increasing 
burden of breast carcinoma significantly increases the workload on both diagnostic and 
treatment facilities. In Africa, women have limited cancer education and access to screening 
for breast carcinoma, and 50-70% of these women that are diagnosed with breast cancer, 
present with advanced breast disease, which in combination with delayed access to treatment 
facilities result in a poor prognosis. 
FNA is a quick, reliable, informative, and cost-effective diagnostic test that can significantly 
improve timely diagnosis of breast carcinoma and prompt referral of patients for definite 
treatment, especially in countries with limited resources, such as South Africa. Despite the 
apparent advantages of FNA and the cell block technique in the diagnostics and theranostics 
of breast carcinoma, there exists a significant knowledge gap regarding the accuracy and 
reliability of FNA and the cell block technique as an integral part of personalised patient care. 
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Chapter 2: Aims and Study design 
2.1 Aims 
• To retrospectively correlate the expression of ER and PR hormone receptors 
performed on BD Cytorich™ Red cell blocks and histological FFPET in chemotherapy 
naive breast carcinomas, by immunochemistry. 
 
• To retrospectively compare the HER2 expression and interpretation between the BD 
Cytorich™ Red cell block and histological FFPET in chemotherapy naive breast 
carcinomas via ICC and IHC respectively. FISH testing for HER2 will be additionally 
performed, on cases that scored 2+ and 3+ and a random selection of negative cases. 
 
• To grade the carcinomas on the cytology smears, using the Robinsons grading system, 
and compare it to histologically graded carcinoma using the Modified Richardson and 
Bloom grading system. 
 
2.2 Hypothesis 
• BD Cytorich™ Red cell blocks and histological FFPET are equally good in 
determining ER and PR hormone receptor expression by means of ICC and IHC, 
respectively 
 
• BD Cytorich™ Red cell blocks and histological FFPET are equally good in 
determining HER2 over expression by means of ICC and IHC, respectively and have 
good correlation with FISH. 
 
• Cytological carcinoma grading will be comparable to the carcinoma grading on 
histological samples. 
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2.3 Study Design and Case Selection 
The archive of the Division of Anatomical Pathology, Department of Pathology, Tygerberg 
Hospital, Stellenbosch University and National Health Laboratory Service (NHLS) was 
searched for patients who had an FNAB done at the divisional FNA Clinic at Tygerberg 
Hospital between January 2013 and December 2015. 
Patients with a primary cytological diagnosis of breast carcinoma, and who had ER, PR and 
HER2 ICC stains performed on BD Cytorich™ Red cell blocks, were identified. These cases 
were cross-checked for available histological FFPET (either core biopsy, surgical excision or 
mastectomy specimens), that were chemotherapy naive and on which IHC stains for ER, PR 
and HER2 were performed. Specimens that did not have these stains performed or that could 
not be retrieved from the archives, had these stains redone (were possible). 
Exclusion Criteria: 
• Tissue specimens collected after chemotherapy. 
• Cell blocks containing insufficient material. 
• Cases with a benign histological diagnosis. 
• Cases with no histological follow-up. 
• Cases with histological diagnosis of DCIS. 
The search identified 609 patients with a primary diagnosis of breast carcinoma. 47% (n = 
285) of the patients had no follow up histological specimen; 22% (n = 132) had histology 
done after chemotherapy administration; 7% (n = 40) of cases had no cells or too few cells on 
cell blocks. Additionally 3.5% (n = 20) of the cytological specimens could not be retrieved 
from the departmental archives. 
132 Samples between 2013 and 2015 were chemotherapy naive and considered suitable for 
this study. All samples were reviewed by a cytotechnologist (EvR) and a pathologist (PS). 
The review included: confirming the original diagnosis, reviewing the grading of the 
carcinomas, scoring the ER, PR and HER2 immunostains on the cytology and histology 
specimens.  
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Throughout this manuscript, the use of the terms ‘cell block’ or ‘BD CytorichTM Red’ will 
always refer to cytology specimens. While the term ‘FFPET’ will always refer to histological 
specimens (i.e. biopsies or excision specimens that were taken and fixed directly in 10% 
buffered formalin for histological processing).  
2.4 Breast cancer grading study population 
Cytological grading was compared to corresponding FFPET grading. The same study 
population that were used for ER and PR analysis were utilised to perform grading. Grading 
was done on conventional cytology Papanicolaou stained smears. Four cases were excluded 
from grading as slides could not be retrieved from the archives.  A total of 128 cytology cases 
were graded using the Robinsons grading system.  
2.5 Ethical approval 
Ethical approval was obtained from the Health Research Ethics Committee, Stellenbosch 
University.  A waiver of consent was obtained due to the retrospective component of this 
study as the results would have no bearing on continuing patient treatment. (S15/10/236). 
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Chapter 3: Cytopathology Methodology 
3.1 FNAB procedure 
After a preliminary on-site diagnosis of breast carcinoma, a separate needle pass was 
performed for the preparation of cell blocks. A 22G or 24G needle and a 5-10ml syringe were 
used to perform the FNAB. Cellular material obtained by a separate needle pass was 
immediately expressed into the vial containing BD Cytorich™ Red preservative fluid. The 
needle was rinsed in the preservative fluid to ensure the collection of sufficient material.  
BD Cytorich™ Red preservative fluid is a product manufactured to preserve cells and small 
tissue fragments for cytological and histological examination. The minimum fixation time is 
30 minutes. The solution furthermore lyses red blood cells and solubilises proteins and is an 
alcohol based haemolytic fixative. The red blood cell membranes are selectively emulsified 
and further disrupted by a combination of alcohol and osmotic lysis.  
The preservative fluid contains less than 1% formaldehyde, which cross-links with globulin 
proteins released from red blood cells.  The proteins are cross-linked before denaturation by 
alcohols and prevented from forming protein super-aggregates. Cell membranes act as 
selective barriers that allow alcohol to pass more rapidly than formaldehyde to the cell 
cytoplasm. The preservative is an aqueous solution made up of ethylene glycol, 
formaldehyde, methanol and isopropanol. Storage of the solution should be limited to 24 
months from the date of manufacture and kept at room temperature, between 15-30ºC. 
The specimens were transported to the cytology specimen reception and processing area in 
the Division of Anatomical Pathology where the aspirated material remained in the BD 
Cytorich™ Red preservative fluid for a minimum of 6 hours and a maximum of 72 hours. 
 
3.2 BD Cytorich™ Red Cell block technique 
Cell blocks were processed in a biological safety cabinet to adhere to standard safety 
protocol, followed by centrifugation at 1500rpm for 10 minutes. The supernatant was then 
decanted into a sterile tube, and the pellet remained in the original cell block tube. Three to 
four drops of plasma were added to the pellet and mixed thoroughly with a plastic pipette. 
Three to four drops of Dade innovin (working solution) were added and mixed thoroughly.  
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Dade innovin reagent is purchased in a lypohilised form that consists of recombinant human 
tissue factor, synthetic phospholipids (thromboplastin, calcium ions, a heparin-neutralised 
compound, buffers and stabilisers (bovine serum albumin). The reagent initiates clotting via 
the extrinsic and common pathways. The reagent can be reconstituted with distilled or 
deionised water and stored at 2 to 8˚C. Contents should be mixed thoroughly to ensure 
complete reconstitution and should be re-mixed before use to ensure a homogenous solution. 
Water containing preservatives should not be used, and the reagent should not be frozen.  
A clot should form within a few minutes due to the activation of the coagulation cascade by 
incubating plasma with thromboplastin and calcium. The clot was placed in a labelled 
cassette and placed in a staining dish containing 10% buffered formalin and a few drops of 
eosin to enhance visualisation of the clot during embedding and cutting. The cell clot 
remained in formalin for 6 to 12 hours before it was transferred to a tissue processor. The cell 
block was processed, sectioned and stained with H&E in the same manner as routine 
histological FFPET specimens. 
 
Figure 3.1: Clot formation, prior to placement in a histology cassette. 
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Chapter 4: Histopathology Methodology 
4.1 Fixation and Tissue processing 
Formalin is routinely used in histopathology laboratories as the standard preferred fixative to 
preserve biological specimens. Formalin is a strong disinfectant and hardens tissue. Table 4.1 
illustrates the solutions used to make up 10% buffered formalin.  
Table 4.1: 10% buffered Formalin preparation 
 
Solutions Quantity 
Formaldehyde 2000ml 
Tap water 18 000ml 
Sodium Di- hydrogen phosphate 80g 
Di- sodium hydrogen phosphate 130g 
 
The buffering salts were dissolved separately in 1000ml tap water by stirring until dissolved. 
The rest of the water was added to fill up to 18 000ml. The concentrated formaldehyde was 
added to make up to 20 000ml. 
Tissue processing (Table 4.2) allows for tissue to be embedded in a solid medium to make it 
firm enough, to provide adequate support and rigidity for the cut of thin tissue sections. The 
first step of the process involves fixation, which preserves the tissue by preventing autolysis 
and putrefaction resulting in tissue that is in a live-like state. The second step involves 
dehydration by immersing the tissue in graded alcohol to remove intracellular and 
extracellular water from the tissue. Alcohol is then removed from the tissue and cleared in 
xylene. Impregnation with paraffin wax, the last step of the tissue processing procedure, 
occurs at a temperature between 55ºC and 65ºC. 
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Table 4.2: Tissue processing program 
 Solutions Time Temperature 
1 Formalin 30 min 40ºC 
2 Formalin 45 min 40ºC 
3 70% Alcohol 30 min 40ºC 
4 80% Alcohol 45 min 40ºC 
5 96% Alcohol 45 min 40ºC 
6 Absolute Alcohol 45 min 40ºC 
7 Absolute Alcohol 45 min 40ºC 
8 Absolute Alcohol 60 min 40ºC 
9 Xylol 60 min 40ºC 
10 Xylol 45 min 40ºC 
11 Wax 45 min 60ºC 
12 Wax 45 min 60ºC 
13 Wax 45 min 60ºC 
14 Wax 45 min 60ºC 
 
4.1.1 Embedding procedure 
The purpose of embedding is to support the impregnated tissue in a wax block to enable 
cutting of thin tissue sections. An embedding machine consists of a reservoir of molten wax 
which is kept at 62 to 65ºC, a hot plate, a cold plate and metal moulds of various sizes. The 
tissue is taken from the impregnation wax bath of the tissue processor and transferred directly 
to the wax reservoir in the embedding machine.  
The orientation of tissue is the most important step, followed by placement in the mould. The 
tissue must be orientated so that it offers the least amount of resistance to the knife. A 
suitable size mould must be selected to allow a space of wax around the tissue, and tissue 
must be placed as flat as possible.  
The mould is then warmed on a hot plate, and a small amount of wax is dispersed into the 
bottom. The tissue is removed from the cassette and orientated correctly with warm forceps 
in the mould. The mould is placed on a cold tray for the tissue to set in the correct position 
and to remove the block from the metal mould easily. The cassette is placed on top of the 
mould and filled with wax. 
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4.1.2 Microtome procedure 
Rotary microtomes are used to cut sections from routine specimens, where the knife is 
stationary, and the block moves up and down. The microtome is used to cut a thin section of 
paraffin-embedded tissue and to mount the section on a slide. 
After embedding and cooling of blocks on a cold plate, the block is clamped in the block 
holder of the microtome. The block needs to be aligned correctly and trimmed to remove 
excess wax covering the tissue. Trimming continues until exposure of the whole surface of 
the tissue. The block is released from the block holder and then placed on an ice tray to allow 
cooling before cutting. There is less friction between the blade and wax if the block is cooled. 
The block is once again securely fitted into the microtome’s block holder. The thickness 
setting on the microtome is 4 microns. A ribbon of sections is cut and placed in a water bath 
and picked up carefully onto a slide. The water bath temperature is set between 40 and 50ºC 
the warm water assists to remove small folds and wrinkles in the wax.  Slides are then 
incubated for 20 minutes before staining. 
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4.2 H&E staining procedure 
The H&E stain is the most widely used histological stain. The haematoxylin component 
stains the cell nuclei blue while the eosin stains the cytoplasm and most connective tissue 
fibres in varying shades and intensities of pink, orange and red. 
Garvey’s alum haematoxylin (Table 4.3) and Mayer’s haematoxylin are used, and both stains 
use the mordant aluminium ammonium sulphate. A combination of Eosin Y and Phloxine B 
are used to counterstain. Two parts of eosin are mixed with one part phloxine to make up the 
stock solution. The working solution consists of equal quantities of stock solution and tap 
water is mixed and allowed to stand for 48 hours before use.  
 
Table 4.3: Garvey’s Haematoxylin ingredients 
 
Solutions Quantity 
Haematoxylin 2.5g 
Absolute alcohol 100ml 
Saturated aqueous potassium alum 45g 
Sodium iodate 0.3g 
Citric acid 1g 
Distilled water 900ml 
*Solution made up to 1000ml 
Method: Haematoxylin is dissolved in absolute alcohol. In a separate glass cylinder, 
Potassium alum is dissolved in distilled water with added heat. The two solutions are 
combined followed by adding sodium iodate and citric acid. The mixture is blended well and 
is stable for several months. 
Scott’s tap water is used as a blueing agent during the H&E staining procedure. Solutions 
used to make up Scott’s tap water are tabulated in Table 4.5. 
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Table 4.4: Scott’s tap water ingredients 
 
Solutions Quantity 
Sodium hydrogen carbonate 3.5g 
Magnesium sulphate 20g 
  Tap water 1000ml 
 
Table 4.5: H&E staining program 
 
Solutions Time 
1. De-wax sections in Xylene 5 min 
2. Rinse in absolute alcohol, 96% alcohol, 70% alcohol and then water  
3. Stain in Garvey’s alum haematoxylin  4- 6 min 
4. Wash in water  
5. Blue in Scott’s tap water  
6. Rinse in 70% alcohol 1 min 
7. Stain in Eosin/Phloxine 1 min 
8. Rinse in 70% alcohol  
9. Dehydrate by washing in 70% alcohol, 96% alcohol and then absolute 
alcohol 
 
10. Clear in Xylene  
11. Mount with Entellan  
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4.3 Immunochemistry 
Immunochemistry is the process of localising proteins in cells by antibodies binding 
specifically to antigens in biological tissue. Immunochemistry performed on histology 
specimens will be referred to as immunohistochemistry and that performed on cytological 
material be referred to as immunocytochemistry. The visualization of antigens via the 
application of a specific antibody to an antigen is performed.  A secondary antibody is added 
to the primary antibody with a chromogenic substrate. The chromogen results in a visible 
reaction at the antigen site. Staining was performed by a Leica BOND III system as 
illustrated in Table 4.6.  
 
Figure 4.1 Illustration of immunohistochemistry method 
(http://www.unizwa.edu.om/content_files/a69171581.jpg) 
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Slide preparation  
Tissue sections were cut from each cell block and FFPET at a thickness of 3 micron per 
section and placed on charged slides, which were baked for 30 min at 70˚C. Slides were 
stained on the BOND machine and covertiles were placed correctly to ensure complete 
staining of the slides.  
Bond Wash concentration 
Bond wash was prepared by adding 100 ml of BOND Wash concentration to 900ml of 
deionised water. 
Primary optimally diluted antibodies 
• ER: Novocastra Estrogen Receptor diluted 1:250 
• PR: Novocastra Progesterone Receptor diluted 1:500 
• HER2: Novocastra HER2 oncoprotein diluted 1:250 
The chromogen used was DAB (diaminobenzidine) which is the colouring substrate. 
Controls  
A known positive control section was included on each slide for immunochemical staining.  
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Table 4.6: Leica BOND III staining program 
 
 Repeats/cycles Time Temperature 
De-wax X3  72˚C 
100% Alcohol X3   
Bond wash X3   
Retrieval  ER&PR X2 20 min 100˚C 
Retrieval HER2 X2 20 min 100˚C 
Bond wash X4   
Bond wash X1 3 min  
Antibodies X1 15 min  
Bond wash X1 2 min  
Bond wash X2 1 min  
Post primary X1 8 min  
Wash  X3   
Polymer  X1 8 min  
Wash  X2 2 min  
De-ionized water X1   
Peroxide block X1 5 min  
Wash  X1 1 min  
Wash  X2   
Distilled water X1   
Mixed DAB refine X1   
Mixed DAB refine X1 10 min  
De-ionized water X3   
Haematoxylin X1 5 min  
De-ionized water X1   
Wash  X1   
De-ionized water X1   
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4.3.1 ER and PR 
The Allred scoring system as illustrated in Table 4.7 was used to determine hormone receptor 
status. This system comprises the sum of the independent scoring of the proportion of 
positive staining tumour cell nuclei as well as the intensity of staining respectively.40,45  
During assessment of ER and PR proportion, all the tumour cells on the slide were taken into 
account and were scored as follows (Tables 4.6 and 4.7):  
 
Table 4.7: ER & PR proportion (Allred scoring system)  
Score Proportion 
0 No staining 
1 <1% 
2 ³ 1% but <10% 
3 ³ 11% and <33% 
4  ³34% and <66% 
5  ³67% and 100% 
 
 
Table 4.8: Staining intensity for FFPET and Cell blocks 
Score Intensity 
0 No staining 
1 Weak staining 
2 Moderate staining 
3 Strong staining 
 
The final interpretation of positive, negative or not interpretable was assigned as follow: 
• Receptor Positive: Proportion plus Intensity score of ³3  
o  ≥1% tumour cells must stain positive. 
o Allred score ≥ 3: 1-10% weakly positive cells 
• Receptor Negative : <1% of any intensity staining 
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4.3.2 HER 2 ASCO/ CAP guidelines46 
The 2013 ASCO/CAP guidelines for HER2 testing state that the time from obtaining the 
specimen (biopsy or excision) to the initiation of tissue fixation should be as short as possible 
and the duration of tissue fixation should be 6 to 72 hours. 
Table 4.9: HER2 scoring system 
 
Score Staining pattern HER2 Status 
0 No staining/ weak membrane staining in <10% of tumour cells Negative 
1+ Weak / partial membrane staining in >10% of tumour  cells Negative 
2+ Moderate membrane staining in >10% of tumour cells or 
Strong circumferential membrane staining in <30% of tumour 
cells 
Indeterminate 
3+ Strong circumferential membrane staining in >10% of tumour 
cells. 
Positive 
 
 
Figure 4.2 HER 2 assay 
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4.4 FISH principle and procedure 
In situ hybridization is a technique that is used for localization and detection of specific DNA 
or RNA sequences in cells, preserved tissue sections, or an entire tissue by hybridizing the 
complementary strand of a nucleotide probe to a particular sequence. These hybrids can be 
visualised by autoradiography for probes labelled radioactively or by development of a 
histochemical chromogen for probes labelled non-isotopically. After a labelled probe is 
annealed to matching sequences in fixed cells or tissue, the hybridized probe is visualised.47 
 
 
Figure 4.3 Illustration of fluorescent in situ hybridization method 
(http://jcp.bmj.com/content/jclinpath/63/3/210/F5.large.jpg) 
 
FISH was performed on BD Cytorich™ Red cell blocks using the PathVysion HER 2 DNA 
Probe kit II and analysis was done using a Zeiss Imager Z1 fluorescence microscope. The 
entire section was analysed and 20 cells were selected and scored by an analyst and results 
were verified by a second analyst at Unistel Laboratories. 
  
Stellenbosch University  https://scholar.sun.ac.za
36 
 
Table 4.10: FISH status ASCO/CAP guidelines.46 
 
Group Ratio HER2 copy number Status 
1 > 2.0 > 4.0 Positive 
2 > 2.0 < 4.0 Positive 
3 < 2.0 > 6.0 Positive 
4 < 2.0 > 4.0, < 6.0 Equivocal 
5 < 2.0 < 4.0 Negative 
 
 
 
Figure 4.4 FISH assay  
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Chapter 5: Microscopic review methodology 
5.1 BD Cytorich™ Red Cell block cellularity 
The Cell block sections that contained at least 10 high power fields (x400) of tumour cells 
and peripheral blood cell elements with at least 10 tumour cells per field will be considered 
sufficient for analysis, as suggested by current published literature.29 Table 5.1 shows the 
classification of cell block cellularity that was used.  
 
Table 5.1: Cell Block cellularity scoring system 
Score Cellularity 
A Less than 20 cells 
B 20 or more cells, less than 100 cells 
C 100 or more cells, less than 1000 cells 
D 1000 or more cells 
 
5.2 ER and PR scoring systems 
Histological FFPET cases stained with ER and PR respectively were reviewed and 
interpreted using the Allred scoring system for proportion and intensity, as illustrated in 
Table 4.7 & 4.8. The proportion and intensity of nuclear staining on cell blocks are currently 
not evaluated and, therefore, not reported in our laboratory. The proportion of nuclear 
staining on cell blocks was calculated according to an internally developed scoring system, as 
illustrated in Table 5.2; these results were then correlated with histological FFPET. 
Table 5.2: Cell block ER and PR proportion scoring system 
Score ER and PR Proportion 
0 Less than 10% tumour cells staining 
1 10% or more, less than 30% tumour cells staining 
2 30% or more, less than 60% tumour cells staining 
3 60%  or more tumour cells staining 
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5.3 HER2 scoring system 
Scoring for reviewed cases was interpreted according to ASCO/CAP guidelines as illustrated 
in Table 4.9. 
 
5.4 Grading scoring systems 
5.4.1 Histology grading system 
 
Table 5.3: Scarf- Bloom- Richardson grading system 
Features Score 
Tubule formation: 
     Majority of tumor >75% 1 
     Moderate degree 10- 75% 2 
     Few or little <10% 3 
Nuclear pleomorphism: 
     Small, uniform cells 1 
     Moderate increase in size, variation 2 
      Marked variation/ pleomorphism 3 
Mitotic counts: 
     0-5  1 
    6-10 2 
    >11 3 
 
Scoring: Grade 1 (well- differentiated): 3-5. Grade 2 (moderately differentiated): 6-7. Grade 3 
(poorly differentiated): 8-9. 
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5.4.2 Cytology grading system 
 
Table 5.4: Robinsons grading system 
Score 
Criteria 1 2 3 
Cell dissociation Mostly clusters Mixture of single cells and 
cells in clusters 
Mostly single cell 
Cell size 1-2 x RBC size 3- 4 x RBC size >5 x RBC size 
Cell uniformity Monomorphic Mildly pleomorphic Pleomorphic 
Nucleoli Indistinct Noticeable Prominent or 
pleomorphic 
Nuclear margin Smooth Folds Buds/ clefts 
Chromatin Vesicular Granular Clumped and cleared 
 
Grade 1: Score 6- 11. Grade2: Score 12- 14. Grade 3: Score 15- 18 
RBC = red blood cell 
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Chapter 6: Cell block cellularity and general findings 
6.1 Results 
6.1.1 Cell block cellularity 
Cell block cellularity as illustrated by Figure 6.1 shows that 49% (n= 65) of cell blocks were 
in group D, which contained 1000 cell and more, and 39% (n= 51) cell blocks were in group 
C, which was interpreted as more than a 100 cells but less than 1000 cells. Cell blocks that 
were in group B were 12% (n= 16). Forty cell blocks revealed no cells or too few cells, fitted 
in group A, and were excluded from the study population. 
 
 
Figure 6.1: Cell block cellularity/ adequacy 
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6.1.2 Mean Age 
Patients presenting with diagnosis of breast cancer had a mean age of 56 years. This study 
presented with a total of 130 females and 2 males. Females presented with a mean age of 56 
and males with a mean age of 60 years. The youngest female was 28 and the oldest was 96. 
The youngest male was 36 and the oldest was 61.  
 
Figure 6.2 Mean age for males and females 
6.1.3 Histology specimen types 
Core needle biopsies were 43.18% (n = 57), tumour excisions were 30.30% (n = 40), 
modified radical mastectomies were 12.88% (n = 17) and simple mastectomies were 13.64% 
(n = 18).  
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Figure 6.3 Histology specimen types. n = 132 
6.1.4 Tumour types 
The most common diagnosis for both cytology and histology was invasive carcinoma no 
specific type (NST) 89% (n = 117) and 86% (n = 114) respectively. Lobular carcinoma 
diagnosis was 0.76% (n = 1) on cytology and 1.52% (n = 2) on histology. Detailed results are 
illustrated in Figure 6.4. 
 
 
*NST: No Specific Type  
 
Figure 6.4 Cytological and Histological tumour type 
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6.1.5 Study population 
 
610 cases were identified from 2013 to 2015 with a primary diagnosis of breast cancer on 
cytology. 285 patients had no histology follow up. 132 patients had histology done after 
chemotherapy. 40 patients had cell blocks with no cells or too few cells. 21 cases could not 
be retrieved from the archive and 132 cases were chemotherapy naive and deemed suitable 
for this study. 
 
 
Figure 6.5 Study population 
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6.2 Discussion 
Cell blocks of adequate cellularity are increasingly being used in adjunct with FNAB smears 
to improve the diagnostic accuracy of FNA cytology.48 Cell blocks can sometimes lack 
adequate cellularity even if conventional smears are abundantly cellular.49 In this study 
87.88% (n=116) of our cell blocks had more than a 100 cells, which is considered sufficient 
for analysis according to Bueno et al. The adequacy and sensitivity of cell blocks depends on 
sampling type, size of specimen and the aspiration technique used.29 
In this study the overall mean patient age was 56. Mean age for females was 56 and for males 
60 years. Age is considered a major risk factor for developing breast carcinoma and the vast 
majority of breast carcinomas occur in women over the age of 50.2 
In this study needle core biopsy made up 43% of all the histology specimen types followed 
by tumour excision (30%). Core needle biopsy is more cost-effective than tumour excision 
and open surgery can be avoided which lowers clinical complications. Tumour excision is 
however considered the method of choice because it is representative of the whole tumour but 
is much more expensive.18–20 
Invasive carcinoma of no specific type comprises approximately 75% of all breast 
carcinomas, which correlates with the finding of this study on cytology and histology 
respectively. Mucinous carcinoma accounts for approximately 2% of all breast carcinomas. 
This study included 9 (6.82%) cases that were diagnosed on cytology and 8 (6.06%) cases 
diagnosed on histology.  
Lobular carcinoma is seen in approximately 5-15% of all breast carcinomas. The current 
study had only 1 (0.76%) case diagnosed on cytology and 2 (1.52%) cases diagnosed on 
histology, illustrating that lobular carcinoma was uncommon in this study. These results 
emphasize the difficultly in correctly identifying lobular carcinoma on cytology. 
There was one neuroendocrine carcinoma, two carcinomas with medullary features and two 
carcinomas with apocrine features diagnosed on histology, none of which were specifically 
diagnosed on cytology. Cytologically these were all diagnosed as carcinoma, NST. 
Carcinomas such as lobular, tubular, papillary or invasive carcinomas of low nuclear grade 
may be difficult to recognise on FNAB and should be confirmed with core needle biopsy.22  
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Chapter 7: ER and PR Analysis 
7.1 Results 
ER was positive in 78% (n = 103) and negative in 22% (n = 29) of the cell block cases. On 
histological FFPET, ER was positive in 80% (n = 105) and negative in 20% (n = 27) of the 
cases.  
Cell block ER positivity showed a sensitivity of 91% and a specificity of 62% (with a 95% 
confidence interval). The positive predictive value was 90% and negative predictive value of 
67%. Table 7.1 tabulates the ER-positive and ER-negative cases in cell blocks and FFPER 
respectively. 
Table 7.1: ER staining results on cell blocks and FFPET. 
 FFPET ER 
Cell block ER Positive Negative Cell block Total 
Positive 94 9 103 
Negative 11 18 29 
FFPET Total 105 27 132 
      
PR was positive in 67% (n = 88) and negative in 33% (n = 44) of the cell block cases. On 
FFPET, PR was positive in 62% (n = 82) and negative in 38% (n = 50) of the cases.  
PR positivity on cell block showed a sensitivity of 85% and a specificity of 84% (with a 95% 
confidence interval). The positive predictive value was 92% and negative predictive was 
74%. Table 7.2 tabulates the PR-positive and PR-negative cases in cell blocks and FFPET 
respectively. 
Table 7.2: PR staining results in cell blocks and FFPET. 
                              FFPET PR 
Cell block PR Positive Negative FFPET Total 
Positive 75 13 88 
Negative 7 37 44 
Cell block Total 82 50 132 
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7.2 Discussion 
The correlation of immunochemical staining for ER and PR on FNAB cell blocks and on 
histological FFPET samples respectively has been under debate for decades. Histological 
FFPET remains the gold standard with proven accuracy and reliability, with a lower rate of 
unsatisfactory samples, and with a higher sensitivity and specificity than cell blocks; however 
as mentioned previously, tissue biopsies (core needle or excision biopsies) have several 
disadvantages such as haematoma, bleeding, increased time and cost to perform the 
procedure, and delays in reporting of the results.  
Various studies have compared FNAB with histological samples but the latter remain 
superior but FNAB advantages contribute greatly as a diagnostic tool. However, FNAB offers 
several advantages as outlined previously, and efforts to improve its specificity and 
sensitivity for the detection of ER and PR remain important.50,51 
This study confirmed the ability to prepare high quality and cellular cell blocks from FNAB 
material. Based on type of treatment(s) planned; ICC can be performed to determine presence 
and over expression of prognostic markers. Patients who would benefit from hormone 
therapy should be identified promptly, therefore accurate reporting is of vital importance for 
prognostic and predictive purposes.31,48,52 
BD Cytorich™ Red fluid was used as a preservative fluid to conserve cellular morphology 
and architecture and to allow cells to appear alcohol-fixed. However cell block preparations 
in this study were fixed in formalin for 2 to 12 hours before histological processing. Maleki et 
al concluded that formalin fixation from 2 to 96 hours provides reliable IHC results. ASCO/ 
CAP guidelines direct that histological biopsy specimens should be fixed for a minimum of 6 
hours and for not more than 48 hours for optimal biomarker assessment. This study suggests 
that BD Cytorich™ Red preservative fluid and 10% buffered formalin fixation has little 
impact on results because the BD Cytorich™ Red cell block technique has shown to have 
good sensitivity and specificity when compared to FFPET. 
BD Cytorich™ Red cell block technique illustrates excellent performance of 91% sensitivity 
with a 95% confidence interval and is therefore reliable for ER assessment. Sensitivity is 
considered to measure the performance of a screening test, thus the sensitivity of the cell 
block test is the probability that someone with breast carcinoma will return a positive test 
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result.53 Results obtained for specificity was 62%, specificity is also the measure of the 
performance of a screening test, which is the probability that someone without breast 
carcinoma will return a negative test result.53 This result was calculated by the overall small 
quantity of ER-negative cases (n = 29) in our study population. Our results correlate well 
with previous studies where cell block sensitivity varies between 60% and 95%.27,28,32 
The positive predictive value (PPV) of a test is the probability that someone who tests 
positive actually has breast carcinoma. BD Cytorich™ Red cell blocks have 90% PPV for ER 
assessment showing good performance for identifying ER-positive tumours. The negative 
predictive value obtained was moderate with 67%, which indicate the probability that some 
negative tests truly do not have ER-negative breast carcinoma. The moderate negative 
predictive value is therefore related to the total amount of negative cases as seen in ER 
specificity. 
PR sensitivity of 85% indicates good performance of the cell block technique together with a 
specificity of 84% with 95% confidence interval.  Positive predictive value of 92% and 
negative predictive value of 74% were obtained. PR sensitivity is lower than ER sensitivity 
possibly due to the conclusion made by Vohra et el. who concluded that the moderate PR 
concordance of 77.5% in their study was attributed to intra-tumoral heterogeneity.27  On the 
other hand, PR specificity is higher than ER specificity, due to the fact that PR has a higher 
amount of overall negative cases (n = 44) than ER-negative cases (n = 29).  
The results in this study can be considered excellent irrespective of numerous factors 
effecting PR positivity. Future research with a larger study population should allow 
identification and elimination of these factors which will ultimately increase reliability and 
accuracy of the BD cell block technique.  
ER positivity analysis also revealed 11 false negative cases and 9 false positive cases. PR 
positivity showed 7 false negative cases and 13 false positive cases. It is difficult to establish 
the reason for these findings, but contributing factors should be identified and eliminated to 
avoid future error. False negative cases may be due to sampling errors, where the sections 
selected did not show ER or PR positivity due to tumour heterogeneity.  
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Generally there are many confounding factors that alter ICC results of cytological material. 
Various studies conclude that pre- analytical factors may have major implications on 
accuracy of results; such as type of fixative, length of fixation, type of antibody (sensitivity 
variation), inefficient antigen retrieval, staining error or analytical factors such as, 
interpretation of scoring systems and borderline cases.48,54,55 
Other causes of false positive results include crushed and degenerate cells or marked 
necrosis, acute inflammation in the background, less specific antibody or an antibody titre 
that is too high. Various reports suggest that some antibodies give a false negative result with 
alcohol-fixation such as estrogen receptor.31 Yet others have reported better results indicating 
that this variation may be attributed to variation in specific antibody manufacturing.56  
It was suggested that discrepancies between cytology and histology samples could be 
ascribed mainly due to tissue heterogeneity, alteration of hormone receptors during the 
storage period or during execution of the tests or, methodology pitfalls.57 
A Standardized, internationally approved scoring system for the reporting of staining of 
hormonal receptors on cytology cell block specimens has not been agreed on as yet. An 
internally developed scoring system was developed to interpret ER and PR proportion 
staining on cell blocks, facilitated comparison of the cell block to the histological FFPET 
specimens.  This scoring system  is listed in Table 5.2 and is a modification of the Allred 
scoring system, that is used on histological specimens and illustrated in Table 4.7.58 The 
reporting of the staining intensity; remains unchanged between the two systems. 
BD Cytorich™ Red cell block yielded excellent results and we believe that our modified 
scoring system provides the necessary information that is needed for determining treatment.  
ER and PR biomarkers were considered positive if ≥10% of tumour cells stained positive 
with any intensity staining; illustrated by Figure 6.2. Thus a proportion of 0, which is staining 
in less than 10% of tumour cells were considered negative on the cell blocks; as illustrated in 
Figure 6.1. The overall positivity for this study was excellent when comparing BD 
Cytorich™ Red cell blocks with histological FFPET specimens considering ER and PR 
sensitivity results obtained. 
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Figure 7.1 (a) Cell Block section showing ER-negative staining (x400 magnification).  (b) Cell Block 
section showing PR positive staining (x400 magnification). BD Cytorich™ Red cell blocks. 
 
 
    
 
Figure 7.2 (a) Cell Block section showing ER intensity 1 staining (x400 magnification). (b) Cell 
Block section showing ER intensity 2 staining (x400 magnification). (c) Cell block section showing 
intensity 3 staining (x400 magnification). BD Cytorich™ Red cell blocks 
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Chapter 8: HER2 Analysis  
8.1 Results 
HER2 IHC staining was performed on 130 cases of the same study population. Two cases 
had to be excluded as the stained slides and respective tissue wax blocks could not be 
retrieved from the archives.  
On the BD Cytorich™ Red cell blocks there were 108 negative cases; 8 cases were 
interpreted as equivocal (2+) and 14 cases as 3+ positive.  
On the histological FFPET, HER2 was negative in 99 cases; equivocal (2+) in 19 cases and 
positive 3+ in 12 cases. These results are tabulated in Table 8.1.  
Cell blocks had an overall agreement of 88% when compared to histological FFPET; with a 
Cohen kappa value of 0, 67. 
 
Table 8.1: HER2 analysis (cytology cell blocks and histological FFPET) 
FFPET HER2 
Cell block HER2 1+ 2+ 3+ Total 
1+ 99 9 0 108 
2+ 0 6 2 8 
3+ 0 4 10 14 
Total 99 19 12 130 
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8.2 Discussion 
HER2 expression is a poor prognostic marker, which correlates with more aggressive 
behaviour and an overall decreased survival. HER2 testing is recommended for all breast 
carcinomas to determine if they are eligible for Trastuzumab® therapy.59  
HER2 testing by immunochemistry was designed to analyse HER2 protein expression with a 
bright field microscope on histological FFPET sections. Immunochemistry is considered to 
be easier and more cost-effective to assess HER2 expression when compared to FISH. 
Immunochemistry is however subjective and semi- quantitative in determining expression 
levels of HER2 protein in breast carcinoma. Factors that influence the sensitivity and 
specificity of IHC include selection of antibody clones and signal detection systems.42 
In this study cell blocks had an overall agreement of 88% when compared with histological 
FFPET. These findings indicate a reputable agreement between the cell block technique and 
histological FFPET. HER2 evaluation produced a kappa value of 0.67, indicating substantial 
agreement. Kappa is a quantitative measure of the magnitude of agreement between tests, 
therefore the cell block technique to determine HER2 status can be considered as an 
important modality for prediction of therapy. 
Nine cases that were negative (0 or 1+) on cell block were scored 2+ (equivocal) on the 
FFPET. Two cases were scored 2+ (equivocal) on cell block and were scored 3+ on FFPET.  
Four cases that were scored 3+ on cell block; were scored 2+ (equivocal) on histological 
FFPET.  
HER2 assessment is prone to error in both cytological and histological material having many 
technical and interpretive challenges. Therefore strict standardization is necessary to maintain 
accuracy and reliability (consistency). Patient’s who may benefit from Trastuzumab® 
treatment, should be selected carefully due to cost and toxicity of treatment. Therefore HER2 
equivocal cases need to be re- examined or submitted for FISH assays. Interpretation of 
HER2 status also requires intact cell membranes and cell to cell interaction.12,27,42  
Figures 8.1 (A and B) as illustrated below were considered negative having no staining or 
granular cytoplasmic staining. Figures 8.2 (A and B) were deemed negative (1+) for weak or 
partial membrane staining in less than 10% of tumour cells. 
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Figure 8.1 (a) Cell block section showing HER2 negative staining (x200). BD Cytorich™ Red cell 
block. (b) Histological section illustrating HER2 negative staining (x400). 
 
 
   
Figure 8.2 (a) Cell block showing HER2 Negative staining, scored as 1+ (x400). (b) HER2 negative 
staining, scored as 1+ on cell block section (x400).  BD Cytorich™ Red cell blocks. 
  
A score of 2+ is illustrated below in Figures 8.3 A and B. These cases had incomplete but 
strong membranous staining in more than 10% of tumour cells.  
   
 
Figure 8.3 (a) Cell block showing HER2 equivocal staining, scored as 2+ (x400). BD Cytorich™ Red 
cell block.  (b) HER2 positive staining scored as 2+ on histological section (x400). 
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Figures 8.4 (A and B) illustrate cases that were interpreted as 3+ on cell block sections. There were 14 
cases on the cell blocks that were scored as 3+, positive staining with strong and complete, 
circumferential membranous staining in more than 10% of tumour cells.  
 
    
 
Figure 8.4 (a) Cell block showing HER2 positive staining, scored as 3+ (x400). (b) HER2 positive 
scored as 3+ on cell block section (x400). BD Cytorich™ Red cell block. 
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Stellenbosch University  https://scholar.sun.ac.za
54 
 
Chapter 9: FISH Analysis 
9.1 Results 
FISH analysis was performed on 25 cases that were randomly selected from the study 
population, and included 7 cases of positive 3+ staining, 4 cases of 2+ equivocal staining and 
14 case of negative (0 or 1+) staining. 
Of the seven 3+ staining cell block cases, all seven were FISH positive for amplification of 
HER2. 
Of the four 2+ staining cell block cases, 3 were FISH positive and one FISH negative. 
Of the Fourteen 1+ staining cell block cases, 3 came back as positive, 9 were negative and 2 
had equivocal results, as listed in Table 9.1. 
One of these fourteen 1+ cases showed a positive FISH result for HER2 amplification. This 
case additionally also stained as 1+ on the histological tissue. 
 
Table 9.1: FISH analysis performed on the Cytology cell block specimens 
 
 HER2 cell block immnostaining   
FISH Cell block 1+ 2+ 3+ Total 
positive 3 3 7 13 
negative 9 1 0 10 
equivocal 2 0 0 2 
Total 14 4 7 25 
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9.2 Discussion 
All the 7 cases that were called positive on the BD Cytorich™ Red cell block 
immunostaining for HER2 were analysed as positive with the FISH probe. 
Three of the four cases that were assessed as being 2+ (equivocal) with the immunostaining 
for HER2, revealed a positive FISH result. One case was FISH negative, indicating, that the 
2+ score was correct and deserved FISH testing, as also required by ASCO Guidelines.  
Three of the 14 cases that were called negative on HER2 immunostaining, showed a positive 
FISH result, with 9 being negative and 2 having an equivocal FISH results. This implies that 
64% of the cases showed a correct result on immunostaining, with a further 12% being 
equivocal. 
The three cases that had a negative score (0 or 1+) on immunostaining but a positive FISH 
result illustrate that more work is needed. This includes a need to improve the standardization 
of the reporting of the immunostaining and a need to further optimize the immunostaining 
technique for the HER antibody on the cell block material.  
Overall, 80% of the cell block cases tested with FISH were correctly assessed on the HER2 
immunostaining.  
Twelve percent (3 cases) were deemed falsely negative on the HER2 immunostaining as they 
returned a positive FISH result. There was also 2 cases (8%) that returned an equivocal FISH 
result and these remain uncertain as to their true HER2 status. 
These numbers are however too small to yield meaningful statistical evaluation and further 
studies are needed. 
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Chapter 10: Breast Cancer Grading 
10.1 Results 
10.1.1 Cytological findings 
 
Cytology showed grade 1 in 33.59% (n= 43) of cases, grade 2 in 39.84% (n= 51) of cases, 
and grade 3 in 26.56% (n= 34) of cases. Detailed results are tabulated in Table 10.3. 
Table 10.1: Robinsons grading parameters analysis 
Parameters/variables Cohen kappa value Agreement associated with 
cytological grade 
Cell dissociation 0.0831 40.30% 
Cell size 0.3070 53.73% 
Uniformity 0.3507 55.97% 
Nucleoli 0.3339 55.97% 
Margin 0.3859 59.70% 
Chromatin 0.3048 54.48% 
 
10.4.2 Histological findings 
 
Histology scored grade 1 in 25.78% (n= 33) of cases, grade 2 in 46.09% (n= 59) of cases, and 
grade 3 in 28.13% (n= 36) of cases. Detailed results are tabulated in Table 10.4. 
Table 10.2: Comparison of Cytological and Histological carcinoma grading 
 Histological grade 
Cytological  
Grade 
1 2 3 Total 
1 15 24 4 43 (33.59%) 
2 13 22 16 51 (39.84%) 
3 5 13 16 34 (26.56%) 
Total 33 (25.78%) 59 (46.09%) 36 (28.13%) 128 (100%) 
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10.4.3 Cytological and histological findings 
The overall agreement was 41.41% when cytology grading was compared to histological 
grading. Cohen kappa value obtained was 0.1055 and z-test was 1.69. Standard error results 
showed a value of 0.0624 with the p-value being < 0.006 (not statistically significant). 
   
 
Figure 10.1 (a) Grade 1 tumour on cytology. (Papanicolaou stain x400) (b) Grade 1 tumour on 
cytology showing small nuclei 1- 2 times the size of a red blood cell. (Papanicolaou stain x400) 
 
   
 
Figure 10.2 (a) Grade 3 on cytology (Papanicolaou stain x1000). (b) Highly pleomorphic cells 
diagnosed grade 3 on histological section (H&E stain x400) 
 
   
 
Figure 10.3 (a) Prominent nucleoli (Papanicolaou stain x1000). (b) Histological section showing 
pleomorphic and prominent nucleoli (H&E stain x400). 
A B 
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Figure 10.4 (a) Illustration of cleft formation (Papanicolaou stain x1000) (b) Illustration of grooves 
(Papanicolaou stain x1000) 
 
   
 
Figure 10.5 (a) Dissociation indicating mostly single cells (papanicolaou stain x400). (b) Cell 
dissociation illustrating mostly clusters (Papanicolaou stain x40) 
 
   
 
Figure 10.6 (a) Illustration of granular chromatin (Papanicolaou stain x400). (b) Illustration of mitotic 
figure illustrated on histological section (H&E stain x400) 
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10.5 Discussion 
Pre-operative grading on FNA samples may be useful for determination of prognosis and 
neo- adjuvant therapy. Histological grading is based on the degree of tubule formation, 
mitosis and nuclear pleomorphism. Tubules and mitoses are difficult to assess on cytology 
and therefore may cause discordance between cytological and histological grading. In 
cytological grading nuclear size, nucleoli, nuclear membrane and chromatin pattern receive 
much more emphasis, which may also lead to increased disparity in grading.44 
In this study, the overall agreement was 41.41% when cytological grading was compared to 
histological grading. This poor agreement implies caution when performing grading on 
cytology specimens.  
Cohen kappa value obtained was 0.1055 and z-test was 1.69. Standard error results showed 
0.0624 and p value was < 0.006. The kappa value is very low indicating a lack of agreement 
between cytological and histological grading. 
A potential source of error may be due to inconsistency during interpretation of the 
measuring tools or variables which are exceptionally subjective; these variables include 
nucleoli, chromatin, margin, dissociation and nuclear size. Therefore these variables are 
subject to errors and inter- observer variation. 
Detection of mitoses and tubules are notoriously difficult in FNA smears. Mitotic figures can 
be seen on cytological smears, but it is not as high as in histological sections. Therefore 
mitotic count is not measured in the Robinsons grading system. 
Nuclear margin, cell uniformity and chromatin pattern are used in histology to evaluate 
nuclear pleomorphism. Nuclear margin was found to influence the cytological score 
according to Jyothi et al.44  In this study nuclear margin is the variable that has the highest 
significance when compared to the final cytological carcinoma grade; and is considered to be 
the most important feature. Dissociation had the lowest agreement and is therefore not a 
significant factor/ variable to use in determining the final grade on cytological smears. 
Chromatin pattern in this study revealed the lowest kappa value as tabulated in Table 10.3 
and is considered not to be statistically significant. This finding might be due to subjectivity 
in assessment or to eye resolution limitations with the light microscope in detecting subtle 
grades of nuclear chromasia and granularity.44 
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Chapter 11: Conclusion 
11.1 Summary of Findings 
The primary aim of patients who are referred to breast clinics is to confirm or exclude 
presence of malignancy. FNAB can be of vital importance in the pre-operative evaluation of 
breast carcinoma. Ancillary techniques performed on cytological material demand 
standardization of pre-analytical, analytical and post-analytical methods. The amount of 
material obtained to conduct ancillary testing is a limiting factor. Specimen collection and 
processing needs to be performed in a manner to optimize both making a correct diagnosis 
and maximizing the amount of tissue available for ancillary studies.  
In the current era of personalized medicine appropriate tissue triaging is of vital importance 
to avoid unnecessary sampling and/or procedures. There is huge pressure to obtain maximum 
amount of information from a tumour with the least amount of intervention and/or 
procedures. This problem is further compounded in a limited resource setting. 
In many cases biopsy specimens are not available and the only source available for ancillary 
testing is FNA cytology material. Though cell blocks are routinely collected and prepared on 
malignant breast specimens, they remain plagued by collection of insufficient material.   
This study has demonstrated that conventional cytology smears that were obtained via a 
minimally invasive, fine needle aspiration biopsy procedure (FNAB) that was performed in a 
dedicated FNAB clinic; could diagnose breast carcinoma correctly. The BD CytorichTM Red 
cell block collection method produced high cellularity cell blocks with excellent results for 
ER, PR and HER2 immunostaining. It also showed that BD CytorichTM Red cell blocks can 
be used for FISH molecular techniques. FNAB cytology offers a safe, reliable, accurate and 
minimally invasive alternative technique for the diagnosis and prognostication of breast 
carcinomas in our setting. 
The grading performed on cytological material did not correlate well with histology in this 
study. Additional studies are needed in order to simplify grading systems that could be used 
on cytology smear specimens. Standardized and simple criteria that can be consistently 
applied are essential and need to be established on cytology FNA material to ultimately 
predict histological grade. 
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